Portal Pump

A revolutionary solution – fully automated, implantable insulin delivery

Portal Diabetes, Inc. is developing the Portal Pump™: the first artificial pancreas
No more carb counting, no more meal announcements, no more sleep interruption
Superior outcomes, superior experience

The products described on this website are in the research and development stage. They are not approved by the U.S. Food and Drug Administration and are not available for clinical use or sale in any country.

Why Portal Diabetes?

Only 20% of adults living with type 1 diabetes (T1D) achieve glycemic targets according to the American Diabetes Association.

The management burden adds up to about 2,000 annual tasks when things go right. The Portal Pump will only involve 5 to 40 tasks annually.

Portal is developing the first artificial pancreas to functionally cure type 1 diabetes, delivering exceptional health outcomes and reducing management burden.

Patients, providers, and payers will each greatly benefit from the Portal Pump.

Know more

About us

Portal Diabetes: developing the first artificial pancreas

Portal is developing the first artificial pancreas, a fully automated insulin delivery system, made possible by the fast pharmacokinetics of insulin delivered to the intraperitoneal space, an implantable pump, heat stable insulin, and modern continuous glucose monitor (CGM) technology. The Portal Pump is anticipated to deliver an average time in range in the 90s while relieving patients of the relentless management burden. Patients will no longer need to provide carbohydrate counts, meal announcements, exercise announcements, or wake in the night to manage their blood glucose. Portal Diabetes endeavors to allow patients to safely forget diabetes by restoring the function of a pancreas, the Portal Pump.

Our Team

The Portal Diabetes team is comprised of talented and experienced people devoted to the mission of bringing the first artificial pancreas to patients living with type 1 diabetes.

Stacy Chambliss

Chief Executive Officer

Lee Hartley

Chief Technology Officer

Ted Randolph

Chief Operations Officer

Austin Smith

Head of Engineering

Nico Varas

Head of Drug Development

Juan Gonzalez

Head of Manufacturing

The Challenge

Diabetes | The Elusive Balancing Act

Patients are overwhelmed

24/7 titration with subcutaneous insulin is required with unpredictable outcomes.
Skin site management; infections, tape allergies
Pump Maintenance
Refrigeration of insulin
Purchasing insulin and disposable supplies
Frequent insurance interaction

Why do 80% of T1D patients fail?

80% of patients fail to achieve the control required to prevent chronic complications, blindness, amputations, and kidney failure
Why is glycemic control worsening?
Why is nothing changing?
Established companies are doing fine. Patients are not.
Management is too burdensome, insulin absorption is slow, nontargeted
The Portal Pump will make management of diabetes effortless

Insulin is not delivered to the normal physiologic site.
‍It’s time for a new approach!

Technology

The Technology

SOLUTION | Portal Pump™

An implantable pump delivers insulin to the right space

Just as it would for a normal pancreas, insulin is delivered directly to the liver.

Rapid uptake of intraperitoneal insulin enables a basic control algorithm to fully automate insulin delivery.

The device is refilled with insulin after weeks or months of therapy. Like a pacemaker or pain pump, the Portal Pump is implanted during an outpatient procedure, where it remains for 5-7 years until a new battery is needed.